Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer

NCT00869206 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT00869206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00869206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2009
Completion date
January 31, 2017
Enrollment
1,822 (actual)
Sites
504

Conditions

As the registry lists them; a condition with its own page is linked.

breast adenocarcinoma, ds stage i plasma cell myeloma, ds stage ii plasma cell myeloma, metastatic malignant neoplasm to the bone, musculoskeletal complication, pain, urinary complications